References

References

Bateman ED, Ferguson GT, Barnes N et al. (2013) Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal May 30 doi: 10.1183/09031936.00200212

Dahl R, Chapman KR, Rudolf M et al. (2013) Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respiratory Medicine 107: 1558−67

European Medicines Agency. European public assessment report for Ultibro Breezhaler. [online; accessed 4 January 2013]

European Medicines Agency. Product information for Ultibro Breezhaler. [online; accessed 4 January 2013]

Mahler DA, Decramer M, D'Urzo A et al. (2013) Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. European Respiratory Journal October 31 doi: 10.1183/09031936.00124013

National Institute for Health and Clinical Excellence (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE clinical guideline 101

National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease. NICE Pathway [online; accessed 4 January 2013]

US National Institutes of Health (2013) CinicalTrials.gov Identifier: NCT01782326 [online; accessed 4 January 2013]

Vogelmeier CF, Bateman ED, Pallante J et al. (2012) Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol—fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. The Lancet Respiratory Medicine 1: 51−60

Wedzicha JA, Decramer M, Ficker JH et al. (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The Lancet Respiratory Medicine 1: 199−209